Savient Pharmaceuticals Inc – ‘424B3’ on 6/15/95

As of:  Thursday, 6/15/95   ·   Accession #:  950110-95-446   ·   File #:  33-83902

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Prospectus   —   Rule 424(b)(3)
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 424B3       Prospectus Supplement                                  2     10K 

424B3
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SUPPLEMENT DATED JUNE 14, 1995

To Prospectus, Dated January 13, 1995, of 

BIO-TECHNOLOGY GENERAL CORP.

6,206,250 Warrants to purchase shares of Common Stock 
at a purchase price of $5.49 per share
6,206,250 shares of Common Stock issuable upon exercise of Warrants 

The following supplements the information contained in the attached   
Prospectus of Bio-Technology General Corp., dated January 13, 1995:             

Page 26 - DESCRIPTION OF CAPITAL STOCK                                

     The Warrants provide that if the Company enters into a Sale Transaction (as
hereinafter defined) at a price per share of the Company's Common Stock less    
than $6.59 (adjusted for any stock splits, stock dividends or similar actions), 
the exercise price of the Warrants will be automatically reduced to a price per 
share of the Company's Common Stock equal to the difference between the Sale    
Price (as hereinafter defined) and $1.10 (adjusted for any stock splits, stock  
dividends or similar actions). For purposes hereof, the term "Sale Transaction" 
shall mean (i) the execution by the Company of a definitive merger agreement    
pursuant to which the outstanding shares of the Company's Common Stock will be  
converted into the right to receive cash, (ii) the execution by the Company of a
definitive asset purchase agreement pursuant to which the Company proposes to   
sell substantially all its assets for cash, securities or a combination thereof 
and thereafter to distribute such consideration to the Company's stockholders,  
or (iii) a third party commences a cash tender offer for all of the Company's   
outstanding Common Stock. For purposes hereof, the term Sale Price shall mean   
(i) in the case of a merger, the cash offered per share of the Company's Common 
Stock, (ii) in the case of an asset sale, the fair market value of the          
consideration to be distributed to the Company's stockholders and (iii) in the  
case of a cash tender offer, the amount of cash offered.                        

424B3
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Page 27 - SELLING SECURITY HOLDERS                                    

The Company has been informed that after the date of the Prospectus D.
Blech & Company, Inc. transferred its Warrants to Biotechnology Investment      
Group, L.L.C. in a transaction exempt from registration under the Securities    
Act. As a result of such transfer, D. Blech & Company, Inc. should be removed   
from the list of Selling Security Holders and Biotechnology Investment Group,   
L.L.C. should be added to the Selling Security Holder list as follows:          

                                                        [Enlarge/Download Table]


                                Number of              Number of                                       
                                Shares of              Shares of              Number of     Number of  
                                Common Stock           Common Stock           Warrants      Warrants   
Selling                         Beneficially           Registered             Beneficially  Registered 
Security Holder                 Owned(1)               Herein(2)              Owned(3)      Herein(3)  
---------------                 ------------           ------------           ------------  -----------
                                                                                                       
Biotechnology Investment                                                                               
   Group, L.L.C.(f)              1,814,432                562,500               562,500        562,500 

-------------                                                                                          
<FN>                                                                                                   
(f)  Beneficial ownership includes 30,575 shares of Common Stock issuable upon                         
     the exercise of warrants issued in the December Private Placement, and                            
     813,333 and 406,666 shares of Common Stock issuable upon the exercise of                          
     warrants with exercise prices of $4.92 and $9.84, respectively, that were                         
     issued by Gynex and which were converted into warrants to purchase shares                         
     of Common Stock of the Company upon the merger of Gynex with and into BTG                         
     Pharmaceuticals Corp., a wholly owned subsidiary of the Company.                                  
</FN>                                                                                                  

     Subsequent to the date of the Prospectus, David Blech, the sole shareholder
of D. Blech & Company, Inc., filed a Schedule 13D which indicates that he       
beneficially owns less than 5% of the Company's Common Stock and that he        
"understands or has reason to believe that substantially all of the shares of   
Common Stock beneficially owned by various trusts for the benefit of [David     
Blech] were sold either voluntarily or pursuant to margin calls or similar      
creditor claims during the period beginning April 1994 and ending November      
1994."                                                                          

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘424B3’ Filing		Date		First		Last			Other Filings
Filed on:		6/15/95
		6/14/95		1					8-A12G/A,  DEF 14A
		1/13/95		1
									List all Filings